Erythropoietin Stimulating Agents Market Scope
The process of producing red blood cells is known as erythropoiesis. A hormone called erythropoietin, which is released by the kidneys and stimulates the bone marrow to make more blood cells, starts the process. Erythropoietin stimulating drugs are pharmaceuticals that work in the same way as erythropoietin to increase the number of blood cells in the body. Anemia can be caused by a range of medical illnesses, including cancer, blood disorders, neurological disorders, chronic renal disease, HIV, and others.
The Erythropoietin Stimulating Agents market study is segmented by Type (Erythropoietin, Epoetin alfa (Procrit, Epogen), Epoetin beta, Epoetin zeta (Silapo, Retacrit), Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta and Others), by Application (Cancer, Hematology, Kidney Disorder, Renal Disorders, Anti-retroviral Treatment, Neural Diseases and Other) and major geographies with country level break-up.
The market for Erythropoietin Stimulating Agents is fiercely competitive, with both worldwide and local players. Amgen, Thermos Fisher Scientific, Johnson & Johnson, F. Hoffmann-La Roche, and Pfizer Inc. are among the market's major participants. Several pharmaceutical companies are developing and producing ESAs after patents expire, and they are forming strategic alliances, such as acquisitions and collaborations, to expand their product portfolio globally. In addition, the report will include an in-depth analysis of major market strategies such as new product development/launch, mergers and acquisitions, partnerships, collaborations and joint ventures, research and development, and regional expansion.
Amgen Inc. (United States), F. Hoffmann La Roche Ltd (Switzerland), Thermo Fisher Scientific (United States), Johnson and Johnson (United States), Pfizer Inc. (United States), BioSidus (Argentina), Biocon (India), Celltrion (South Korea), Roche (Switzerland), Intas Pharmaceuticals (India) and Teva Pharmaceutical Industries (Israel) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Erythropoietin Stimulating Agents market by Type, Application and Region.
On the basis of geography, the market of Erythropoietin Stimulating Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In July 2020, PT Kalbe Genexine Biologics has started a Phase III clinical trial of Efepoetin Alfa for the treatment of anemia associated with chronic renal disease patients who are not on dialysis. and In Feb 2020, At Samsung Medical Center, a multicentre randomized study on the efficacy of Ferinject, an intravenous iron injection, in cancer patients with anemia has begun.
- Increasing Incidences of Chronic Kidney Disease and Cancer
- Increase in Production of Biosimilar Drugs Globally
- Emerging Countries for Biosimilar Erythropoietin Stimulating Agents
- Increasing Drug manufacturers in the developing countries
- Side Effects Associated with Erythropoietin Stimulating Agents to Restrict the Market Growth
- Strict government regulation in the market
Key Target AudienceIndustry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Erythropoietin Stimulating Agents Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2027.